Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa
Encinitas, California--(Newsfile Corp. - September 18, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced the completion of the final patient's last endpoint evaluation from the ABACUS study of KIO-301. KIO-301 is A molecular photoswitch being evaluated in a Phase 1B clinical trial for vision restoration in late-stage Retinitis Pigmentosa (RP). Topline study results will be reported November 4 at the upcoming American Academy of Ophthalmology annual meeting. ABACUS enrolled six...
2023-09-18 7:00 AM EDT
Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosa
Encinitas, California--(Newsfile Corp. - September 14, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced that results from the ABACUS study of KIO-301 in patients with late-stage retinitis pigmentosa will be presented at the American Academy of Ophthalmology (AAO 2023) conference on November 4, 2023. The late-breaking abstract has been accepted for presentation at the retinal subspecialty day and will include findings from all six participants and 12...
2023-09-14 7:01 AM EDT
Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27
Encinitas, California--(Newsfile Corp. - September 1, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announced that the Company's Special Meeting of Stockholders (the "Special Meeting") held on August 31, 2023 at 9:00 a.m. Pacific Time was convened and adjourned, without any business being conducted, due to lack of the required quorum.A quorum consists of one third of the voting power of the outstanding shares of the Company entitled to vote generally in the...
2023-09-01 7:00 AM EDT
Kiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal Diseases
Encinitas, California--(Newsfile Corp. - August 29, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites you to participate in a webinar highlighting the progress of molecular photoswitches in retinitis pigmentosa and the future development plans in additional inherited retinal diseases such as choroideremia. The webinar is being hosted by the Choroideremia Research Foundation (CRF) and will include presentations from and discussions with retinal disease expert Christine Kay, M.D.,...
2023-08-29 1:43 PM EDT
Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitis
Encinitas, California--(Newsfile Corp. - August 23, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it has been granted U.S. (Patent # 11,730,716) and European Patents covering local ocular delivery of the KIO-100 family of non-steroidal, anti-inflammatory small molecules. This intellectual property (IP) further protects Kiora's pipeline by covering multiple small molecule analogs, delivery methods, and several inflammatory-related therapeutic...
2023-08-23 7:00 AM EDT
Kiora Pharmaceuticals Webcasts Its Investor Presentation from the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
Encinitas, California--(Newsfile Corp. - August 16, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) welcomes investors to watch the Company's online presentation from the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference. As part of the talk, Kiora President & CEO Brian Strem, Ph.D., details the Company's sharpened focus on rare retinal diseases. This includes continued development of KIO-301 for the treatment of Retinitis Pigmentosa and expanding clinical development of KIO-301 for...
2023-08-16 7:00 AM EDT
Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress
Including Choroideremia and Stargardt's DiseaseManagement Sharpens Clinical Development Focus on Rare Retinal Diseases and Will Seek Partnerships to Advance its Promising but Non-Core Anterior Segment Therapeutic Applications Encinitas, California--(Newsfile...
2023-08-08 7:00 AM EDT
Kiora Pharmaceuticals, Inc. and Choroideremia Research Foundation Partner to Advance Novel Choroideremia Treatment
Encinitas, California--(Newsfile Corp. - August 3, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), a clinical-stage ophthalmic pharmaceutical company developing novel therapeutics for patients with high unmet needs, and the Choroideremia Research Foundation (CRF), the largest organization in the world focused on the search for a cure for choroideremia (CHM), have partnered to advance a potential new treatment for patients with CHM. Choroideremia is a rare, inherited retinal disease that...
2023-08-03 7:00 AM EDT
Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors
Encinitas, California--(Newsfile Corp. - August 1, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) has appointed Carmine Stengone as an independent member to the Company's board of directors. Stengone currently serves as the President and CEO of Pipeline Therapeutics, a company developing precision medicines to treat neurodegenerative diseases.Carmine Stengone, Director, Kiora Pharmaceuticals To view an enhanced
2023-08-01 7:00 AM EDT
Kiora Pharmaceuticals Receives $1.2 Million in Research Tax Credits to Advance the Treatment of Ophthalmic Disease
Encinitas, California--(Newsfile Corp. - July 5, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced its wholly owned subsidiaries have received, in aggregate, $1.2 million related to research tax incentives from the Austrian and Australian governments for research expenditures performed in 2021 and 2022. The funds were received as part of government incentive programs to conduct critical research and development within those countries. The funds will be used to support Kiora's...
2023-07-05 7:00 AM EDT
Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
Kiora would have owed to SentrxSentrx gains access to Kiora's recently issued patents covering the combination of KIO-201 and antibiotics for veterinary useKiora will receive a royalty on net sales of products covered by licensed patentsEncinitas, California--(Newsfile Corp. - June 15, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora") and Sentrx Animal Care ("Sentrx") announced today they have amended their existing licensing agreement for patents and technology related to Kiora's...
2023-06-15 7:00 AM EDT
Kiora Pharmaceuticals to Present at Upcoming Investor Conferences
Encinitas, California--(Newsfile Corp. - June 14, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced its President & CEO, Brian Strem, Ph.D., will participate in two upcoming investor conferences. The Healthcare Virtual Conference hosted by Maxim GroupJune 20, 2023 from 10:00 to 10:30 am EDTDr. Strem will provide a brief overview followed by a 20-to-25-minute live Q&AInvestors are invited to view the presentation here (https://m-vest.com/events/healthcare-06202023)Life Science...
2023-06-14 8:00 AM EDT
Kiora Pharmaceuticals Announces Closing of $6.3 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
Encinitas, California--(Newsfile Corp. - June 6, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced the closing of an underwritten public offering for gross proceeds of approximately $6.3 million, which includes full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses.The offering was comprised of (i) 1,447,628 shares of common...
2023-06-06 4:30 PM EDT
Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
Encinitas, California--(Newsfile Corp. - June 2, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced the pricing of an underwritten public offering for gross proceeds of approximately $5.5 million prior to deducting underwriting discounts and commissions and offering expenses.The offering is comprised of (i) 1,447,628 shares of common stock, (ii) 3,908 shares of Series F Convertible Preferred Stock, (iii) 5,000,000 Class C Warrants with an initial...
2023-06-02 8:30 AM EDT
Kiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments
Encinitas, California--(Newsfile Corp. - May 9, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) announced its first quarter 2023 results, during which time it significantly advanced its ocular drug development pipeline of clinical-stage candidates for the treatment of Retinitis Pigmentosa (RP), Persistent Corneal Epithelial Defects (PCEDs), and the Ocular Presentation of Rheumatoid Arthritis (OPRA).CEO Commentary"This has been a pivotal quarter for our business resulting in several recently...
2023-05-09 7:00 AM EDT
Kiora Pharmaceuticals Presents Encore Imaging Results of KIO-301 for Retinitis Pigmentosa at ASNR 2023 Meeting
Encinitas, California--(Newsfile Corp. - May 1, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) announced today an encore presentation on KIO-301 neuroimaging results at The American Society of Neuroradiology 2023 Meeting in Chicago. The late-breaking abstract presentation titled "Functional Vision Reanimation in Retinitis Pigmentosa using an Intravitreal 'Photoswitch' Molecule (KIO-301): Functional MRI Protocol and Preliminary In-Human Observations" will be presented by Christen Barras, MBBS,...
2023-05-01 7:00 AM EDT
Kiora's Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in Patients Who Are Blind
Encinitas, California--(Newsfile Corp. - April 27, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) presented preliminary results from an ongoing clinical trial showing its investigational drug, KIO-301, has the potential to restore light perception in patients who are blind or living with ultra-low vision due to retinitis pigmentosa. KIO-301 is a light-sensing small molecule designed to reactivate visual function of the eye in response to light. The results were presented today at the...
2023-04-27 2:55 PM EDT
Kiora Pharmaceuticals' KIO-201 Heals Wounds in Phase 2 Trial of Patients with Persistent Corneal Epithelial Defects
Encinitas, California--(Newsfile Corp. - April 26, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) presented results of a Phase 2 clinical trial for KIO-201 treating patients with Persistent Corneal Epithelial Defects (PCEDs) at the Association for Research in Vision and Ophthalmology (ARVO) Meeting in New Orleans.KIO-201 is a chemically modified and cross-linked form of hyaluronic acid designed to accelerate corneal wound healing. The results of the clinical trial demonstrate that KIO-201 is a...
2023-04-26 7:00 AM EDT
Inherited Retinal Disease Expert, Mark Pennesi, M.D., Ph.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board
Encinitas, California--(Newsfile Corp. - April 21, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) has appointed Mark Pennesi, M.D., Ph.D., the Kenneth C. Swan Endowed Professor in Ophthalmology and Molecular and Medical Genetics and the Chief of the Paul H. Casey Ophthalmic Genetics Division at the Casey Eye Institute at Oregon Health & Science University, to their Scientific Advisory Board. As a member of the Scientific Advisory Board, his expertise and insights will contribute to the...
2023-04-21 7:00 AM EDT
Kiora Pharmaceuticals Initiates Phase 2 Trial of KIO-101 for the Treatment of Ocular Presentation of Autoimmune Diseases
Encinitas, California--(Newsfile Corp. - April 17, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) enrolled the first patient in its Phase 2 trial of KIO-101 in the treatment of the Ocular Presentations of Rheumatoid Arthritis and other autoimmune diseases (OPRA+). This clinical trial is a phase 2, multi-center, controlled, randomized, double-masked study targeting enrollment of up to 120 patients. Participants will receive one of two doses of KIO-101 (0.15% and 0.30%) or a placebo. Efficacy...
2023-04-17 7:00 AM EDT